From 27–29 January, members of the TBVAC-HORIZON consortium gathered in Les Diablerets, Switzerland, for the project’s third annual progress meeting. The event brought together 56 participants, including consortium members, invited guests, and representatives from the Scientific Advisory Board (SAB) and Ethics Advisory Board (EAB), to review scientific progress and discuss the final phase of the project.

The meeting featured 24 scientific progress presentations, along with managerial updates, each followed by dedicated discussion time that enabled detailed exchanges and lively Q&A sessions between presenters and participants.

Alongside the scientific sessions, the consortium held its General Assembly, focusing on ongoing consortium activities and looked ahead to the final year of TBVAC-HORIZON and explored potential pathways for collaboration and research activities beyond the project’s completion. The Scientific Advisory Board and Ethics Advisory Board also met during the event and presented their observations and recommendations to the Steering Committee. Their feedback provided valuable guidance for refining ongoing research activities. In addition, work package meetings were held following the plenary sessions, allowing teams to discuss ongoing work and coordination. With the end of TBVAC-HORIZON approaching in 2027, the consortium organised an informal brainstorming workshop as well. The session attracted strong participation with discussions focused on maintaining collaboration and cohesion within the consortium after the project concludes.

The consortium meeting was preceded by the TBVI Symposium. This year’s symposium centred on the theme “Innovating and diversifying the TB Vaccine Pipeline”, including sessions on mechanisms of action, preclinical mucosal vaccine candidates, accelerating clinical development, and ensuring public health impact through early roll-out preparation. The programme also included panel discussions and interactive exchanges.

Altogether, the meeting once again highlighted the strength of the TBVAC-HORIZON consortium and the collaborative spirit driving the project forward. As the project enters its final stage, the continued commitment and cooperation among partners remain essential to advancing tuberculosis vaccine research and sustaining the consortium’s momentum beyond the project’s lifetime.